Recently, an antibody that blocks the CD47/SIRPα axis (Hu5F9-G4 from Forty seven Inc.)was shown to clinically effective in B-cell lymphomas when given in combination with the anti-CD20 antibody rituximab20. Here, SIRPA is linked to B-cell non-Hodgkin lymphoma.